Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma

Hisateru Komatsu, Takaaki Masuda, Tomohiro Iguchi, Sho Nambara, Kuniaki Sato, Quingjang Hu, Hidenari Hirata, Shuhei Ito, Hidetoshi Eguchi, Keishi Sugimachi, Yuichiro Doki, Masaki Mori, Koshi Mimori

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Background/Aim: Fanconi anemia complementation group D2 (FANCD2) gene is vitally involved in DNA damage responses. We investigated the clinical significance of FANCD2 expression in hepatocellular carcinoma (HCC). Patients and Methods: FANCD2 mRNA expression of resected HCC tissues was assessed in two HCC cohorts; Our cases (n=111), and The Cancer Genome Atlas (TCGA; n=371). Gene set enrichment analysis (GSEA) was conducted using the TCGA dataset. Proliferation and invasion assays were performed using siRNAs, and the effect of inhibition of the mechanistic target of rapamycin (mTOR) pathway was evaluated. Results: FANCD2 expression was up-regulated in tumor tissues. Cases with high FANCD2 expression had poorer prognoses in both cohorts, and were associated with larger tumor size and invasive phenotypes. FANCD2 knockdown attenuated proliferation and invasion of HCC cells. FANCD2 expression was suppressed by mTOR inhibition. GSEA supported these findings. Conclusion: Elevated FANCD2 expression in HCC could be a novel biomarker for poor prognosis with potential therapeutic relevance.

元の言語英語
ページ(範囲)1083-1090
ページ数8
ジャーナルAnticancer research
37
発行部数3
DOI
出版物ステータス出版済み - 3 2017

Fingerprint

Fanconi Anemia
Hepatocellular Carcinoma
Gene Expression
Neoplasms
Sirolimus
Genes
Atlases
DNA Damage
Biomarkers
Genome
Phenotype
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma. / Komatsu, Hisateru; Masuda, Takaaki; Iguchi, Tomohiro; Nambara, Sho; Sato, Kuniaki; Hu, Quingjang; Hirata, Hidenari; Ito, Shuhei; Eguchi, Hidetoshi; Sugimachi, Keishi; Doki, Yuichiro; Mori, Masaki; Mimori, Koshi.

:: Anticancer research, 巻 37, 番号 3, 03.2017, p. 1083-1090.

研究成果: ジャーナルへの寄稿記事

Komatsu, H, Masuda, T, Iguchi, T, Nambara, S, Sato, K, Hu, Q, Hirata, H, Ito, S, Eguchi, H, Sugimachi, K, Doki, Y, Mori, M & Mimori, K 2017, 'Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma', Anticancer research, 巻. 37, 番号 3, pp. 1083-1090. https://doi.org/10.21873/anticanres.11420
Komatsu, Hisateru ; Masuda, Takaaki ; Iguchi, Tomohiro ; Nambara, Sho ; Sato, Kuniaki ; Hu, Quingjang ; Hirata, Hidenari ; Ito, Shuhei ; Eguchi, Hidetoshi ; Sugimachi, Keishi ; Doki, Yuichiro ; Mori, Masaki ; Mimori, Koshi. / Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma. :: Anticancer research. 2017 ; 巻 37, 番号 3. pp. 1083-1090.
@article{02d36e9e2b354eb9a579effea657c8f9,
title = "Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma",
abstract = "Background/Aim: Fanconi anemia complementation group D2 (FANCD2) gene is vitally involved in DNA damage responses. We investigated the clinical significance of FANCD2 expression in hepatocellular carcinoma (HCC). Patients and Methods: FANCD2 mRNA expression of resected HCC tissues was assessed in two HCC cohorts; Our cases (n=111), and The Cancer Genome Atlas (TCGA; n=371). Gene set enrichment analysis (GSEA) was conducted using the TCGA dataset. Proliferation and invasion assays were performed using siRNAs, and the effect of inhibition of the mechanistic target of rapamycin (mTOR) pathway was evaluated. Results: FANCD2 expression was up-regulated in tumor tissues. Cases with high FANCD2 expression had poorer prognoses in both cohorts, and were associated with larger tumor size and invasive phenotypes. FANCD2 knockdown attenuated proliferation and invasion of HCC cells. FANCD2 expression was suppressed by mTOR inhibition. GSEA supported these findings. Conclusion: Elevated FANCD2 expression in HCC could be a novel biomarker for poor prognosis with potential therapeutic relevance.",
author = "Hisateru Komatsu and Takaaki Masuda and Tomohiro Iguchi and Sho Nambara and Kuniaki Sato and Quingjang Hu and Hidenari Hirata and Shuhei Ito and Hidetoshi Eguchi and Keishi Sugimachi and Yuichiro Doki and Masaki Mori and Koshi Mimori",
year = "2017",
month = "3",
doi = "10.21873/anticanres.11420",
language = "English",
volume = "37",
pages = "1083--1090",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Clinical significance of fancd2 gene expression and its association with tumor progression in hepatocellular carcinoma

AU - Komatsu, Hisateru

AU - Masuda, Takaaki

AU - Iguchi, Tomohiro

AU - Nambara, Sho

AU - Sato, Kuniaki

AU - Hu, Quingjang

AU - Hirata, Hidenari

AU - Ito, Shuhei

AU - Eguchi, Hidetoshi

AU - Sugimachi, Keishi

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Mimori, Koshi

PY - 2017/3

Y1 - 2017/3

N2 - Background/Aim: Fanconi anemia complementation group D2 (FANCD2) gene is vitally involved in DNA damage responses. We investigated the clinical significance of FANCD2 expression in hepatocellular carcinoma (HCC). Patients and Methods: FANCD2 mRNA expression of resected HCC tissues was assessed in two HCC cohorts; Our cases (n=111), and The Cancer Genome Atlas (TCGA; n=371). Gene set enrichment analysis (GSEA) was conducted using the TCGA dataset. Proliferation and invasion assays were performed using siRNAs, and the effect of inhibition of the mechanistic target of rapamycin (mTOR) pathway was evaluated. Results: FANCD2 expression was up-regulated in tumor tissues. Cases with high FANCD2 expression had poorer prognoses in both cohorts, and were associated with larger tumor size and invasive phenotypes. FANCD2 knockdown attenuated proliferation and invasion of HCC cells. FANCD2 expression was suppressed by mTOR inhibition. GSEA supported these findings. Conclusion: Elevated FANCD2 expression in HCC could be a novel biomarker for poor prognosis with potential therapeutic relevance.

AB - Background/Aim: Fanconi anemia complementation group D2 (FANCD2) gene is vitally involved in DNA damage responses. We investigated the clinical significance of FANCD2 expression in hepatocellular carcinoma (HCC). Patients and Methods: FANCD2 mRNA expression of resected HCC tissues was assessed in two HCC cohorts; Our cases (n=111), and The Cancer Genome Atlas (TCGA; n=371). Gene set enrichment analysis (GSEA) was conducted using the TCGA dataset. Proliferation and invasion assays were performed using siRNAs, and the effect of inhibition of the mechanistic target of rapamycin (mTOR) pathway was evaluated. Results: FANCD2 expression was up-regulated in tumor tissues. Cases with high FANCD2 expression had poorer prognoses in both cohorts, and were associated with larger tumor size and invasive phenotypes. FANCD2 knockdown attenuated proliferation and invasion of HCC cells. FANCD2 expression was suppressed by mTOR inhibition. GSEA supported these findings. Conclusion: Elevated FANCD2 expression in HCC could be a novel biomarker for poor prognosis with potential therapeutic relevance.

UR - http://www.scopus.com/inward/record.url?scp=85015908112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015908112&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11420

DO - 10.21873/anticanres.11420

M3 - Article

C2 - 28314268

AN - SCOPUS:85015908112

VL - 37

SP - 1083

EP - 1090

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -